Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an options trading signal again: unusual options activity screeners and strategies. FREE 30 Day Trial

Stocks | Futures | Watchlist | More
or

Scisparc Ltd (SPRC)

Scisparc Ltd (SPRC)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,033
  • Shares Outstanding, K 1,037
  • Annual Sales, $ 0 K
  • Annual Income, $ -5,790 K
  • 60-Month Beta 0.18
  • Price/Sales 0.58
  • Price/Cash Flow N/A
  • Price/Book 0.14
Trade SPRC with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm 0.00
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 07/28/22
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/22
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year N/A
  • Growth Rate Est. (year over year) unch

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.9400 +6.04%
on 08/15/22
2.2000 -54.69%
on 08/01/22
-0.6832 (-40.67%)
since 07/15/22
3-Month
0.9400 +6.04%
on 08/15/22
3.9499 -74.76%
on 05/24/22
-2.0732 (-67.53%)
since 05/13/22

Most Recent Stories

More News
SciSparc Announces Israeli Ministry of Health Approval to Conduct its Clinical Trial in Autism Spectrum Disorder

The trial's objectives are to evaluate the safety, tolerability and efficacy of SciSparc's SCI-210 in children and adolescents with ASD TEL AVIV,...

SPRC : 0.9968 (-11.00%)
SciSparc Signs Clinical Trial Agreement with Yale University to Conduct its Phase IIb Trial in Tourette Syndrome

The addition of a U.S. site will allow SciSparc to accelerate trial recruitment and further development of novel treatments for patients in need TEL...

SPRC : 0.9968 (-11.00%)
SciSparc Announces Expanding its Clinical Operations to Include a U.S. Site Towards its Phase IIb Trial with its Proprietary SCI-110 for the Treatment of Tourette Syndrome

TEL AVIV, Israel, July 08, 2022 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical...

SPRC : 0.9968 (-11.00%)
SciSparc's JV MitoCareX Bio Launches its Advanced New Laboratory Facility

The new facility will serve the JV’s development of potential cancer drugs TEL AVIV, Israel, July 07, 2022 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq:...

SPRC : 0.9968 (-11.00%)
Traders News Source Interviews Oz Adler Chief Executive Officer at SciSparc Ltd.

NEW YORK, NY / ACCESSWIRE / July 7, 2022 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid cap publicly traded companies recently issued a...

SPRC : 0.9968 (-11.00%)
R&D Efforts for Central Nervous System (CNS) Therapeutics Have Resulted in Hopeful Novel Drug-Delivery Solutions

Palm Beach, FL – June 29 2022 – FinancialNewsMedia.com News Commentary – In the central nervous system (CNS) therapeutics market, large and small pharmaceutical companies are highly investing in...

SPRC : 0.9968 (-11.00%)
DNLI : 37.61 (-1.31%)
SAGE : 43.27 (+0.65%)
SAVA : 20.19 (-1.13%)
ICPT : 18.19 (+3.35%)
R&D Efforts for Central Nervous System (CNS) Therapeutics Have Resulted in Hopeful Novel Drug-Delivery Solutions

/PRNewswire/ -- In the central nervous system (CNS) therapeutics market, large and small pharmaceutical companies are highly investing in the development of...

SPRC : 0.9968 (-11.00%)
DNLI : 37.61 (-1.31%)
SAGE : 43.27 (+0.65%)
SAVA : 20.19 (-1.13%)
ICPT : 18.19 (+3.35%)
SciSparc Successfully Completed The Development of its Proprietary Drug Candidate SCI-110 for its Upcoming Phase IIb Study In Tourette Syndrome

TEL AVIV, Israel, June 29, 2022 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (the "Company" or "SciSparc"), a specialty, clinical-stage...

SPRC : 0.9968 (-11.00%)
SciSparc Announces Ethics Committee Approval to Conduct its Clinical Trial in Autism Spectrum Disorder

The Soroka University Ethics Committee Approval Received to Conduct a Clinical trial with SciSparc’s Proprietary SCI-210 Treatment TEL AVIV, Israel, June ...

SPRC : 0.9968 (-11.00%)
SciSparc Reinforces its New JV for Targeting Discovery with a Global Expert in the Field of Mitochondrial Transport Proteins

JV Targets Potential Drugs for Cancers and Infectious Diseases Tel Aviv, Israel, June 15, 2022 (GLOBE NEWSWIRE) --  SciSparc Ltd. (Nasdaq: SPRC) (the...

SPRC : 0.9968 (-11.00%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell and ranks in the Top 1% of all short term signal directions.

Long term indicators fully support a continuation of the trend.

The market is in highly oversold territory. Beware of a trend reversal.

See More Share

Business Summary

SciSparc Ltd. is a specialty clinical-stage pharmaceutical company. It focuses on the development of therapies to treat disorders of the central nervous system. The company's product pipeline includes SCI-110, SCI-160 and SCI-210. SciSparc Ltd. is based in TEL AVIV, Israel.

See More

Key Turning Points

3rd Resistance Point 1.6612
2nd Resistance Point 1.5056
1st Resistance Point 1.2512
Last Price 0.9968
1st Support Level 0.8412
2nd Support Level 0.6856
3rd Support Level 0.4312

See More

52-Week High 8.5000
Fibonacci 61.8% 5.2530
Fibonacci 50% 4.2501
Fibonacci 38.2% 3.2471
Last Price 0.9968
52-Week Low 0.0001

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar